Additional Listing

Skyepharma plc (the "Company")

Block Listing Application

An application has been made to the UK Listing Authority ("UKLA") and the London Stock Exchange for the listing of 1,100,000 ordinary shares of £1.00 each ("Ordinary Shares") to be admitted to the UKLA Official List and to trade on the London Stock Exchange.

These shares are being reserved under a block listing and will be issued to the Company's Employee Benefit Trusts to enable those trusts to be in a position to meet demand from the exercise of share options pursuant to the Company's 2012 Long Term Incentive Plan and its 2014 International Share Incentive Plan.

It is expected that the admission of the Ordinary Shares will become effective on 22 March 2016. These Ordinary Shares will rank pari passu with existing Ordinary Shares of the Company.

Enquiries:

Antony Taylor, Assistant Company Secretary, Tel. 020 7881 1173

About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com